EPHA2 and non-small cell lung carcinoma: Thus far, no EphA2 interference strategies are used in the clinical setting of NSCLC, yet multiple ways to intrude with EphA2 signaling have been described for anti-tumor purposes, including antibodies, blocking peptides, kinase inhibitors and small molecules that act as antagonists or agonists towards EphA2 (reviewed in Baudet et al. [59] and Hughes and Virag [60]).